Diabetes is a disease characterized by the body's inability to sufficiently produce insulin to properly metabolize carbohydrates. The three main forms the condition are Type 1, Type 2, and gestational diabetes. Type 1 diabetes is a chronic disease characterized by destruction of beta-cells of the pancreas. Type 2 diabetes develops when the body becomes resistant to the effects of insulin. Gestational diabetes is usually a temporary disorder occurring during pregnancy when insulin resistance develops due to hormonal changes and weight gain.
Gerson Lehrman Group Council Members are available to discuss Diabetes via phone consultations, live meetings, surveys, and other custom GLG products and services.
Find, engage, and manageSM experts today through the GLG platform
GLG Council Members are leading experts including academics, scientists, and industry specialists
Medical DirectorSuburban Hospital.
PresidentClose Concerns
Professor of Medicine and Pediatrics REGENTS OF THE UNIVERSITY OF COLORADO
Director of General Internal MedicineSAINT LOUIS UNIVERSITY
Vice President of Clinical AffairsEvidence Based Medicine, Inc.
Study groups are populations of experts knowledgeable on specific sub-topics within a broader industry
News analyses are expert commentaries on current events, written by Council Members who are available for follow up consultations
Fresh Hope for Diabetes Patients
October 15, 2009
ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com
The success of ONGLYZA (saxagliptin) will largely depend on its long-term safety. Saxagliptin is the second drug from this class to be approved in Europe and the US - Merck's Januvia (sitagliptin) was the first. Saxagliptin has had to overcome several new regulatory hurdles as a resultof...
Is the End of the Beginning of Diabetes Coming?
October 11, 2009
Andromeda Biotech Consummates Deal with Teva for the Commercialization of DiaPep277, its Late Stage Development Drug for Type 1 Diabetes | www.pipelinereview.com
Teva's global operations and recognition in association with many generic drugs of different classes and for different indications across many speciaties will be immensely helpful in marketing DiaPep277 worldwide.
Diabetes Care Article Shows Sustained Benefits of CGM
September 18, 2009
Kelly Close, President, Close Concerns
Sustained Benefit of Continuous Glucose Monitoring on HbA1c, Glucose Profiles, and Hypoglycemia in Adults with Type 1 Diabetes | care.diabetesjournals.org
A study by the JDRF CGM study group published in Diabetes Care showed sustained benefits of CGM use on A1c, glucose profiles, and rates of hypoglycemia in intensively managed adult type 1 diabetes patients. Patients spent significantly more time with glucose levels in the range of 71-180 mg/dl (3.9-10...
Amylin Partners with Biocon to Develop Novel Diabetes Therapeutic
September 15, 2009
Kelly Close, President, Close Concerns
Amylin and Biocon to partner on diabetes drug | www.forbes.com
Amylin Pharmaceuticals has entered into an agreement with Biocon to jointly develop, commercialize, and manufacture a novel anti-diabetes therapeutic. Amylin will contribute its peptide hormone development expertise, pursuing its renowned phybrid technology. Biocon will help manufacture the compound,...
September 21, 2009
Glenmark’s novel molecule for Diabetes, Melogliptin to enter phase III trials | www.pipelinereview.com
Yet another gliptin drug for diabetes is to start phse 3 trials.